OncoMatch/Clinical Trials/NCT06266338
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
Is NCT06266338 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Lenvatinib for cervix cancer.
Treatment: Pembrolizumab · Lenvatinib — The main purpose of this study is to gather information about an investigational drug combination, Lenvatinib in combination with pembrolizumab, that may help to treat cervical cancers. In this study, we are looking to see whether the combination of lenvatinib and pembrolizumab has any effect on slowing tumor growth in cervical cancer tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage IVB
Metastatic disease required
recurrent or metastatic. Measurable disease based on RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Exception: within 2 weeks prior to allocation
Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to allocation.
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids. 2 weeks or fewer of palliative radiotherapy for non-CNS disease, with a 1-week washout, is permitted.
Has received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities requiring corticosteroids.
Cannot have received: live vaccine or live-attenuated vaccine
Exception: within 30 days before the first dose of study intervention. Killed vaccines allowed.
Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
Cannot have received: investigational agent or device
Exception: within 4 weeks prior to study intervention administration
Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
Lab requirements
Blood counts
Adequate organ and marrow function as defined in the following table (Table 2). Specimens must be collected within 10 days prior to the start of study intervention.
Kidney function
Adequate organ and marrow function as defined in the following table (Table 2). Specimens must be collected within 10 days prior to the start of study intervention.
Liver function
Adequate organ and marrow function as defined in the following table (Table 2). Specimens must be collected within 10 days prior to the start of study intervention.
Cardiac function
LVEF below institutional normal range (MUGA or ECHO) excluded; QTcF >480 ms excluded; clinically significant cardiovascular disease within 12 months excluded.
Have adequate organ and marrow function as defined in the following table (Table 2). LVEF below the institutional (or local laboratory) normal range, as determined by multigated acquisition (MUGA) or echocardiogram (ECHO) [excluded]. Prolongation of QTcF interval to >480 ms [excluded]. Clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify